MISSISSAUGA, Ontario, March 20, 2017 /PRNewswire/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) (Aralez or the Company) today announced that Adrian Adams, the Chief Executive Officer of the Company, acquired an additional 500,000 shares of the Company's common stock on March 15, 2017 in open-market purchases. 4/5/2016 · Aralez Pharmaceuticals Inc. graduated from TSX Venture Exchange and commenced trading on Toronto Stock Exchange on February 9, 2016. Aralez Pharmaceuticals was the second-best performing company in the Clean Technology & Life Sciences sector on the 2016 TSX Venture 50. For more information, please visit www.aralez.com.

Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ and TSX: ARZ) is a global specialty pharmaceutical company focused on delivering meaningful products to improve patients’ lives, while creating shareholder value by acquiring, developing and commercializing products primarily in cardiovascular disease and other specialty areas. The requested symbol was not found in our database. Try searching for some other symbol on Yahoo Finance Aralez Pharmaceuticals earned a news impact score of -3.3 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the next several days. View News Stories for Aralez Pharmaceuticals. TMX facilitates fully electronic trading on Canada’s premier equities Exchanges, Toronto Stock Exchange (TSX), TSX Venture Exchange (TSXV) and TSX Alpha Exchange Company profile page for Aralez Pharmaceuticals Inc including stock price, company news, press releases, executives, board members, and contact information

AcelRx Pharmaceuticals Inc's shares surged 30 percent on Wednesday after U.S. Food and Administration staff said the company's opioid treatment was safe 

1/16/2018 · Aralez Pharmaceuticals Inc (TSX:ARZ), a CADCA$149.82M small-cap, operates in the healthcare industry, which continues to be affected by the sustained During the day the stock fluctuated 0.00% from a day low at $0.03 to a day high of $0.03. Quick summary: 30 day high of the ARLZ stock price was $0.04 and low was $0.03. 90 day high was $0.44 and low was $0.03. 52 week high for Aralez Pharmaceuticals Inc - $2.98 and low - $0.03. MISSISSAUGA, Ontario, March 20, 2017 /PRNewswire/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) (Aralez or the Company) today announced that Adrian Adams, the Chief Executive Officer of the Company, acquired an additional 500,000 shares of the Company's common stock on March 15, 2017 in open-market purchases. 4/5/2016 · Aralez Pharmaceuticals Inc. graduated from TSX Venture Exchange and commenced trading on Toronto Stock Exchange on February 9, 2016. Aralez Pharmaceuticals was the second-best performing company in the Clean Technology & Life Sciences sector on the 2016 TSX Venture 50. For more information, please visit www.aralez.com. 60-Month Beta: Coefficient that measures the volatility of a stock's returns relative to the market (S&P 500). It is based on a 60-month historical regression of the return on the stock onto the return on the S&P 500. Price/Sales: Latest closing price divided by the last 12 months of revenue/sales per share. 9/20/2016 · The Toronto Stock Exchange (TSX) has close to 1,500 listed companies—and that includes numerous pharmaceutical stocks. For life science investors, it’s an incredibly attractive market: not only is the TSX based in a country that is economically and politically stable, it’s also proven to be one of the world’s top-performing markets. Cipher Pharmaceuticals Inc is a specialty pharmaceutical company, focused on Dermatology. The firm and its subsidiaries develop and acquire products that fulfill unmet medical needs and manage the required clinical development and regulatory process.

Aralez Pharmaceuticals – The stock was down -76.7% in 2Q-2018 following the reporting of 1Q-2018 financial results, at which time the company also announced it was planning to discontinue its U.S.

13 Dec 2017 View our latest analysis for Aralez Pharmaceuticals TSX:ARZ mix comprising of active stock pickers, in particular levered hedge funds, which 

8 Sep 2016 Aralez Pharmaceuticals CEO Adrian Adams, fifth from left, opened the Toronto Stock Exchange on April 5. The company's shares began trading 

3/20/2017 · In addition to Mr. Adams, members of Aralez’s Board of Directors and executive management team recently acquired approximately 90,000 shares of the Company’s common stock in open market purchases. About Aralez Pharmaceuticals Inc. Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ and TSX:ARZ) is a global specialty pharmaceutical company focused on Aralez Pharmaceuticals ROIC % is -14.07% as of today(2019-11-25). Aralez Pharmaceuticals ROIC % explanation, calculation, historical data and more Aralez Pharmaceuticals has 216 employees and is headquartered in Canada. Aralez Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in delivering products to improve patients’ lives by acquiring, developing and commercializing products in cardiovascular, pain and other specialty areas. 5/9/2017 · Aralez Reports First Quarter 2017 Financial Results Canada NewsWire MISSISSAUGA, Ontario, May 9, 2017 -First Quarter 2017 Net Revenues

News and Media for Aralez Pharmaceuticals Inc. (ARZ:CA) Sector News

3/20/2017 · In addition to Mr. Adams, members of Aralez’s Board of Directors and executive management team recently acquired approximately 90,000 shares of the Company’s common stock in open market purchases. About Aralez Pharmaceuticals Inc. Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ and TSX:ARZ) is a global specialty pharmaceutical company focused on

Subramanian brings more than 20 years’ experience in finance and operations strategy to Ocugen, serving most recently as CFO for Aralez Pharmaceuticals.